HBV Cure vignet
Meeting category
Date(s)
2 Nov 2022
Location
Toronto, Canada
Meeting type
Hybrid Meeting
Organizers

International Workshop on HBV Cure 2022

Related Enduring Materials

Enduring Materials
Program of HBV Cure 2022
Session 1 -
Chairs
Marion Peters, MD
Northwestern University, United States
Scott Fung, MD, FRCPC
Toronto General Hospital, Toronto, Canada
New Therapeutic Combination Trials – What Are Their Potential to Achieve a Cure?
Mark Sulkowski, MD
Johns Hopkins University, United States
Is Therapy-Induced HBs Decline the Same as Naturally Low HBs?
Jordan Feld, MD, MPH
Toronto Centre for Liver Disease, Canada
What to Watch: Preclinical Therapeutics with Novel Mechanisms of Action
Massimo Levrero, MD
Hopital de la Croix-Rousse, France
Session 2 -
Chairs
Harry Janssen, MD, PhD
Erasmus MC, University Hospital Rotterdam, the Netherlands / Toronto Centre for Liver Disease, Canada
Mark Sulkowski, MD
Johns Hopkins University, United States
Toxicity Profiles of Checkpoint Inhibition - What to Expect and When to Be Concerned
Morven Cunningham, MBBS, MRCP (UK), PhD
University Health Network / UHN Toronto General Hospital, Canada
Therapy Induced Flares Associated With HBsAg Decline (ASO/PD-1/Stop Nuc/Naps/siRNA?)
Man-Fung Yuen, MBBS, MD, PhD, DSc
University of Hong Kong and Li Shu Fan Medical Foundation, Hong Kong
Why We Should Be Careful Using NA Withdrawal as a Therapeutic Option
Pietro Lampertico, MD, PhD
University of Milan, Italy
Session 3: Clinical Immunology and Immunotherapy Updates -
Chairs
Adam Gehring, PhD
Toronto Centre for Liver Disease, Canada
Pietro Lampertico, MD, PhD
University of Milan, Italy
HBV-Specific T Cell Profile Associated with Functional Cure
Georg Lauer, PhD, MD
Massachusetts General Hospital/ Harvard Medical School, United States
Prospects for Long-Term Anti-HBs and the Vaccinal Effect
Andre Arizpe, PharmD
Vir Biotechnology, Inc., United States
ImmTAV®: Initial Data on a T Cell Receptor Bispecific (ENVxCD3) In People With Chronic HBV
Lucy Dorrell, MBBS, MD, FRCP
Immunocore / Oxford University, United Kingdom
Session 4: Update on Viral Targets for HBV/HDV Therapy -
Chairs:
Massimo Levrero, MD
Hopital de la Croix-Rousse, France
Jordan Feld, MD, MPH
Toronto Centre for Liver Disease, Canada
How HBV RNA and HBcrAg Relate to cccDNA Transcriptional Activity
Barbara Testoni, PhD
Institut National de la Santé et de la Recherche Médicale (INSERM), France
Does the Cam-N Jnj-6379 Contribute to the Antiviral Activity of the Sirna Jnj-3989 in Chronic Hepatitis B? Lessons Learned From Reef-1 and -2 Studies.
Michael Biermer, MD
Janssen Pharmaceutica, Belgium
Evidence of T Cell Restoration after siRNA Therapy
Emily Thi, PhD
Arbutus Biopharma Corporation, United States
ALT/virologic Profiles in Bepi Responders vs. Non-Responders
Stuart Kendrick, MD, PhD, MRCP
GSK / Cambridge University Hospitals, United Kingdom
Development of Assembly Next Generation Core Inhibitors
Grace Wang, MD
Assembly Biosciences, Inc., United States
Bulevirtide - Data from Real World Usage after Approval in Europe
John Flaherty, PharmD
Gilead Sciences, United States
Session 5: Panel Discussion -
Chairs
Harry Janssen, MD, PhD
Erasmus MC, University Hospital Rotterdam, the Netherlands / Toronto Centre for Liver Disease, Canada
Adam Gehring, PhD
Toronto Centre for Liver Disease, Canada
AASLD Preview
Adam Gehring, PhD
Toronto Centre for Liver Disease, Canada
Roundtable: Discussing the Major Hurdles in the Current Landscape of HBV Therapies: 1. Prediction of Response 2. Plateauing responses 3. Immune Restoration and 4. Individualizing Treatment
Georg Lauer, PhD, MD
Massachusetts General Hospital/ Harvard Medical School, United States
Barbara Testoni, PhD
Institut National de la Santé et de la Recherche Médicale (INSERM), France
Pietro Lampertico, MD, PhD
University of Milan, Italy
Overview
Welcome!
Group photo 22

The International Workshop on HBV Cure 2022 took place as a hybrid workshop on 2 November 2022 in Toronto, Canada.

Since 2014, the International Workshop on HBV Cure has been a scientific platform acting as a catalyst to accelerate the progress for achieving a cure. Around the globe, more than 250 million people live with hepatitis B (HBV). The purpose of the workshop is to inform the participants about the developments in the work to find a cure for HBV. The meeting will be highly interactive with input from experts out of the arena of basic, translational, and clinical HBV research.

The field of HBV treatment is undergoing major changes and is on the verge of a paradigm shift. The many new treatment options that are becoming available provide great hopes for decreasing the burden of the disease, simplifying treatment, and potentially curing and eradicating HBV infection.

In order to optimize curative treatment for HBV, outstanding speakers from around the globe will share the newest therapeutic options for viral hepatitis, and experts will discuss the path forward to cure this deadly disease, leading to liver cirrhosis and liver cancer. Questions on which endpoints to use in therapeutic trials and how to combine different agents targeting the virus and/or immune system will be extensively discussed.

This workshop also brings together global interdisciplinary experts to provide a framework for how academia and industry should collaborate to achieve the goal of curing hepatitis B.

Program Directors 2022
Harry Janssen 2019
Harry Janssen, MD, PhD
Erasmus MC, University Hospital Rotterdam, the Netherlands / Toronto Centre for Liver Disease, Canada
General Information
  • If you missed the previous edition of the International Workshop on HBV Cure 2021, you can still watch the enduring materials. Presentations and slides are publicly available here
Venue
The venue of the 9th International Workshop on HBV Cure will be:

DoubleTree by Hilton Toronto Downtown
108 Chestnut Street
Toronto, Ontario M5G1R3
Canada

Website: torontodowntown.doubletree.com
Networking Dinner
Donatello Restaurant
37 Elm St.
Toronto, ON, M5G 1H1
http://www.donatellorestaurant.ca/
COVID-19 Update
In response to the changing COVID-19 situation, the International Workshop on HBV Cure 2022 will be held as a hybrid workshop

We are available to answer any questions or concerns that you may have about your participation at the International Workshop on HBV Cure 2022. For more information, please contact us at eva.vamvounaki@amededu.com.

To stay updated on developments about the International Workshop on HBV Cure 2022, make sure you are signed up for our newsletter.
Unique Features
- Invited lectures from international experts

- Interactive roundtable discussions

- Ample time for discussion
Who Should Attend?
- Clinicians
- Researchers
- Academia
- Industry
- Government representatives
Meeting Objectives
The objectives of this workshop are to:

- Discuss how to reach an HBV functional cure with newly developed agents targeting the immune system or the viral replication cycle;
- Develop endpoints and better biomarkers for these studies; and
- Discuss how new agents should be combined to reach the goal of a functional cure.
Learning Objectives
After attending this workshop, participants will be able to:

- Critically evaluate biomarkers used in clinical HBV studies;
- Outline advances made to cure HBV; and
- Critically assess current approaches taken to achieve the development of a functional cure.
Code of Conduct
All attendees, speakers, co-organizers, partners, endorsers, suppliers, volunteers, and employees at any of our programs are expected to observe our Code of Conduct. We cannot tolerate any form of discrimination, harassment, disrespect, or the marginalization of those involved in our programs. All participants of VE and AME-organized programs are expected to treat others with dignity and respect at all times.

Any individual who feels discriminated against, harassed, disrespected, or marginalized is encouraged to report the incident(s) to VE and AME via info@amededu.com or to one of our on-site personnel.

Any participant who is found to have exhibited any inappropriate conduct or behavior against others may be removed from the program.
Practical Information
Certificate of Attendance
A certificate of attendance will be sent to participants that successfully complete the program and post-meeting survey.
Language
The official language of the meeting is English.
Disclaimer
This workshop is intended for educational purposes only and aims to offer participants the opportunity to share information. The Organizing Secretariat of this event, AME and VE, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this meeting. AME and VE disclaim all liability for injuries or losses of whatever nature incurred by individuals attending the workshop.
Liability and Insurance
By registering for the workshop participants agree that the organizers do not accept responsibility for medical-, travel- or personal insurance. Participants are advised to take out their own insurance policies.
Photographs, Audio, and Video Recording
Photographs, audio, and video recordings are not permitted at the official workshop sessions. Only the official medical writer appointed by the organization may make recordings. All presentations will be posted here as soon as possible after the workshop is finished, provided the speaker has given permission to do so.
Committees
Program Directors
Harry Janssen 2019
Harry Janssen, MD, PhD
Erasmus MC, University Hospital Rotterdam, the Netherlands / Toronto Centre for Liver Disease, Canada
Organizing Committee

The members of the Organizing Committee are a group of carefully selected experts and inspirational leaders in their respective fields. They meet frequently to discuss the scientific program of the workshop and identify interesting topics and candidate speakers.

Support
Silver Level
Principal Supporter
Supporter Level
Friend Level

Support Our Initiative

Financial backing helps us deliver an impactful meeting experience for the benefit of healthcare professionals, researchers, and community representatives involved in HBV Cure.
 
This collaboration plays a vital role in both the organizational as well as scientific success of the program.
 
To show your commitment to the cause and get in touch with us for a tailored support package, please contact Rikke Puggaard-Rode via rikke.rode@amededu.com
 
Benefits of Support 
By supporting this program, we can offer the following advantages for your company.* Please contact us for the most recent support level benefits for this program.

  • Symposium opportunities
  • Non-commercial interviews with company representatives
  • Verbal acknowledgment during the program 
  • Discounted and complimentary registrations for your representatives
  • Company acknowledgment on digital meeting materials including but not limited to newsletters, flyers, the streaming platform, and our website
  • Company acknowledgment on printed meeting materials including but not limited to banners and the program book
  • Digital and printed advertising opportunities 
  • Social media shout-outs
  • Logo on the conference bag 

 
* Subject to the support level

Endorsers
Previous Editions
Language